TITAN PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.09 USD | +1.72% |
|
-3.14% | -14.06% |
| Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.39 | 11.14 | 23.29 | 10.11 | 11.46 | 6.215 |
| Enterprise Value (EV) 1 | 12.41 | 10.36 | 18.68 | 4.374 | 8.706 | 0.0198 |
| P/E ratio | -1.69 x | -0.27 x | -0.68 x | -1.13 x | -1.03 x | -1.11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.63 x | 3.08 x | 4.81 x | 6.63 x | 20.6 x | 33.8 x |
| EV / Revenue | 1.87 x | 2.87 x | 3.86 x | 2.87 x | 15.6 x | 0.11 x |
| EV / EBITDA | -1.57 x | -0.62 x | -2.65 x | -0.48 x | -0.87 x | -0 x |
| EV / FCF | -2.08 x | -1.12 x | -5.01 x | -0.96 x | -1.84 x | -0 x |
| FCF Yield | -48% | -89.3% | -20% | -105% | -54.3% | -28,458% |
| Price to Book | 2.55 x | 7.77 x | 6.65 x | 1.97 x | 8.63 x | 0.97 x |
| Nbr of stocks (in thousands) | 21.7 | 95.6 | 354 | 496 | 731 | 753 |
| Reference price 2 | 802.8 | 116.5 | 65.80 | 20.40 | 15.66 | 8.250 |
| Announcement Date | 4/1/19 | 3/30/20 | 3/31/21 | 3/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6.618 | 3.611 | 4.838 | 1.526 | 0.557 | 0.184 |
| EBITDA 1 | -7.884 | -16.6 | -7.059 | -9.133 | -10.04 | -7.165 |
| EBIT 1 | -8.264 | -16.84 | -7.351 | -9.354 | -10.24 | -7.277 |
| Operating Margin | -124.87% | -466.46% | -151.94% | -612.98% | -1,837.52% | -3,954.89% |
| Earnings before Tax (EBT) 1 | -9.023 | -16.46 | -7.407 | -8.776 | -10.21 | -5.569 |
| Net income 1 | -9.023 | -16.46 | -18.24 | -8.776 | -10.21 | -5.569 |
| Net margin | -136.34% | -455.77% | -377.06% | -575.1% | -1,832.32% | -3,026.63% |
| EPS 2 | -473.7 | -432.0 | -96.70 | -18.04 | -15.19 | -7.406 |
| Free Cash Flow 1 | -5.955 | -9.248 | -3.728 | -4.573 | -4.727 | -5.646 |
| FCF margin | -89.99% | -256.1% | -77.06% | -299.69% | -848.63% | -3,068.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/19 | 3/30/20 | 3/31/21 | 3/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | 0.264 | - | 0.15 | 0.095 |
| EBITDA | - | - | - | - |
| EBIT 1 | -1.908 | - | -2.442 | -2.643 |
| Operating Margin | -722.73% | - | -1,628% | -2,782.11% |
| Earnings before Tax (EBT) 1 | -1.915 | - | -2.462 | -2.638 |
| Net income 1 | -1.915 | -2.54 | -2.462 | -2.638 |
| Net margin | -725.38% | - | -1,641.33% | -2,776.84% |
| EPS 2 | -3.800 | -4.800 | -3.600 | -3.600 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 11/15/21 | 5/16/22 | 8/11/22 | 11/14/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 4.98 | 0.78 | 4.6 | 5.74 | 2.75 | 6.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.96 | -9.25 | -3.73 | -4.57 | -4.73 | -5.65 |
| ROE (net income / shareholders' equity) | -235% | -398% | -298% | -202% | -314% | -139% |
| ROA (Net income/ Total Assets) | -44.9% | -89.2% | -52.2% | -72.7% | -106% | -74.9% |
| Assets 1 | 20.09 | 18.46 | 34.96 | 12.07 | 9.614 | 7.435 |
| Book Value Per Share 2 | 315.0 | 15.00 | 9.890 | 10.40 | 1.820 | 8.500 |
| Cash Flow per Share 2 | 429.0 | 54.60 | 15.20 | 12.20 | 3.910 | 8.650 |
| Capex 1 | 0.42 | 0.26 | 0.54 | 0.02 | - | 0 |
| Capex / Sales | 6.29% | 7.09% | 11.16% | 1.51% | - | 1.09% |
| Announcement Date | 4/1/19 | 3/30/20 | 3/31/21 | 3/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.06% | 6.48M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TTNP Stock
- Financials Titan Pharmaceuticals, Inc.
